Extending use of existing Alzheimer's drug could delay move into nursing home

October 27, 2015
Diagram of the brain of a person with Alzheimer's Disease. Credit: Wikipedia/public domain.

Newly-released follow-up analysis from a 2012 clinical trial led by a UK-based research team suggests that continuing treatment of the commonly-prescribed dementia drug donepezil into the later stages of Alzheimer's could reduce a person's likelihood of moving into a nursing home.

As part of an original clinical trial called DOMINO-AD (Donepezil and Memantine in Moderate to Severe Alzheimer's Disease), which reported its primary outcome data in 2012, a UK-wide team of researchers and clinicians recruited 295 study volunteers from 15 different memory centres across England and Scotland. All of the volunteers had a diagnosis of moderate to severe Alzheimer's disease and had been taking the drug donepezil for at least 3 months. They had to have been taking a dose of 10mg donepezil per day for at least the last six weeks and were living at home – either independently or with a family member.

Donepezil (also known by the brand name Aricept) is one of the few drugs available to help with the symptoms of Alzheimer's disease. It currently has a licence in the UK for people with mild to moderate Alzheimer's and its use in the NHS is recommended for people at these stages of their illness. A second drug called memantine is recommended for use in people with severe Alzheimer's.

The original trial set out to investigate whether continued treatment with donepezil could also have benefits for those with severe Alzheimer's, either alone or in combination with memantine. The researchers compared this to people who were taken off the drug completely. The team did this through a multi-centre, randomised, placebo-controlled clinical trial over 52 weeks.

The trial results announced in 2012 suggested modest benefits on memory and thinking and day-to-day activities in those people who continued to receive donepezil compared to those taken off the drug. While this was the primary outcome of the trial, the researchers have completed a secondary analysis of the data to investigate whether the different combinations of drugs allowed people with Alzheimer's to live at home for longer.

After the initial 52 weeks of defined treatment, the volunteers' ongoing treatment was decided by their individual doctors. The research team recorded where each volunteer was living at the end of the 52 week period, as well as following the volunteers with phone calls for a further three years to find out if and when they had moved into a nursing home.

The team found that those volunteers who had continued treatment with donepezil were less likely to move into a care home in the first year of the study than those who had been taken off the drug. After the first year, this benefit was no longer apparent, with no difference in the number of people who moved into nursing homes between the different treatment groups over the following three years. They also found that starting treatment with memantine had no impact on whether someone moved into a care home over the course of the study.

Dr Simon Ridley, Director of Research at Alzheimer's Research UK said:

"This study is not testing new treatments for Alzheimer's but looking at the effectiveness of current symptomatic treatments in people in the later stages of the disease. The new analysis builds on an earlier clinical trial that reported modest benefits on cognition and day-to-day activities when treatment with the donepezil was continued into the later stages of Alzheimer's. While the findings suggest that treatment with donepezil in people with advanced Alzheimer's could help them to stay at home for longer, the authors highlight that the results are exploratory and we know that the factors influencing a move to care are complex.

"This study addresses the important issue of improving treatment for those in the moderate to severe stages of Alzheimer's disease. With only a handful of symptomatic treatments available to treat Alzheimer's, it is vital that we better understand the most effective ways to use these drugs to help improve quality of life. Increased investment in dementia research is critical, both to improve the use of current symptomatic treatments and to find treatments that can halt the spread of damage through the brain."

Explore further: Commonly used dementia drugs can help more patients with Alzheimer's

Related Stories

Commonly used dementia drugs can help more patients with Alzheimer's

March 7, 2012
The dementia drug donepezil (Aricept), already widely used to treat mild to moderate Alzheimer's disease, can also help in moderate to severe patients, according to a report funded by the UK Medical Research Council (MRC) ...

Alzheimer's drug could prevent bone fractures

September 21, 2015
The most common drug used to treat Alzheimer's disease increases bone mass in mice, according to one of the first research articles published in the new open access journal Heliyon. The authors of the study, from Saitama ...

Investigational therapy focuses on slowing progression in mild to moderate Alzheimer's

August 21, 2014
Patients with mild to moderate Alzheimer's disease currently have no treatment options to slow brain cell deterioration. Researchers at Houston Methodist's Nantz National Alzheimer Center are studying an investigational drug ...

Aricept helps moderate to severe Alzheimer's too

March 8, 2012
Alzheimer's disease patients who are taking a commonly prescribed drug can still benefit from it after they progress to moderate-to-severe illness, when it can be tough to tell whether it's doing any good, a new study says.

Antipsychotics initiated frequently and used for long term in Alzheimer's patients

October 14, 2015
Antipsychotic drugs are initiated in patients with Alzheimer's disease (AD) more frequently than in the general population - already 2-3 years before the Alzheimer's diagnosis, according to a new study from the University ...

Phase II clinical trial for the Alzheimer's Disease drug

June 9, 2014
Fujifilm Holdings Corporation is to accelerate the development of the Alzheimer's Disease drug "T-817MA" following the commencement of a Phase II clinical trial in late May by its group company, Toyama Chemical, in Japan. ...

Recommended for you

Dementia with Lewy bodies: Unique genetic profile identified

December 15, 2017
Dementia with Lewy bodies has a unique genetic profile, distinct from those of Alzheimer's disease or Parkinson's disease, according to the first large-scale genetic study of this common type of dementia.

Major cause of dementia discovered

December 11, 2017
An international team of scientists have confirmed the discovery of a major cause of dementia, with important implications for possible treatment and diagnosis.

Canola oil linked to worsened memory and learning ability in Alzheimer's

December 7, 2017
Canola oil is one of the most widely consumed vegetable oils in the world, yet surprisingly little is known about its effects on health. Now, a new study published online December 7 in the journal Scientific Reports by researchers ...

Genetics study suggests that education reduces risk of Alzheimer's disease

December 7, 2017
The theory that education protects against Alzheimer's disease has been given further weight by new research from the University of Cambridge, funded by the European Union. The study is published today in the BMJ.

Healthy mitochondria could stop Alzheimer's

December 6, 2017
Alzheimer's disease is the most common form of dementia and neurodegeneration worldwide. A major hallmark of the disease is the accumulation of toxic plaques in the brain, formed by the abnormal aggregation of a protein called ...

Alzheimer's damage in mice reduced with compound that targets APOE gene

December 6, 2017
People who carry the APOE4 genetic variant face a substantial risk for developing Alzheimer's disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.